Intravitreal injection technique and monitoring: Updated guidelines of an expert panel

Retina

Volumn 34, Issue , 2014, Pages S1-S18

  Avery, Robert L ^a   Bakri, Sophie J ^b   Blumenkranz, Mark S ^c   Brucker, Alexander J ^d   Cunningham, Emmett T ^c,e,f,g   D'amico, Donald J ^h   Dugel, Pravin U ⁱ   Flynn, Harry W ^j   Freund, K Bailey ^k   Haller, Julia A ^l   Jumper, J Michael ^e,g   Liebmann, Jeffrey M ^m   McCannel, Colin A ⁿ   Mieler, William F ^o   Ta, Christopher N ^c   Williams, George A ^p  

^a California Retina Consultants and Research Foundation   (United States)

^b MAYO CLINIC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g WEST COAST RETINA MEDICAL GROUP   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^k VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^l WILLS EYE HOSPITAL   (United States)

^m NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

ⁿ JULES STEIN EYE INSTITUTE   (United States)

^o UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^p OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; BEVACIZUMAB; CEFAZOLIN; CEFTAZIDIME; CLINDAMYCIN; CORTICOSTEROID; DEXAMETHASONE; FOSCARNET; GANCICLOVIR; IODINE; LOCAL ANESTHETIC AGENT; METHOTREXATE; OCRIPLASMIN; PEGAPTANIB; POVIDONE; RANIBIZUMAB; TOBRAMYCIN; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VANCOMYCIN; VORICONAZOLE; DRUG; TOPICAL ANTIINFECTIVE AGENT;

AGE RELATED MACULAR DEGENERATION; ALLERGY; ANTICOAGULATION; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG CONTAMINATION; ENDOPHTHALMITIS; EYE SURGERY; EYELID; FOLLOW UP; GLAUCOMA; HOSPITAL DISCHARGE; HUMAN; INJECTION SITE; INJECTION SITE INFECTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MACULAR EDEMA; MONITORING; NEEDLE; OPHTHALMOLOGIST; PRACTICE GUIDELINE; REVIEW; SURGICAL PATIENT; ANTIBIOTIC PROPHYLAXIS; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; PHYSIOLOGIC MONITORING; PROCEDURES; VITREOUS BODY;

ANESTHETICS, LOCAL; ANTI-INFECTIVE AGENTS, LOCAL; ANTIBIOTIC PROPHYLAXIS; HUMANS; INTRAVITREAL INJECTIONS; MONITORING, PHYSIOLOGIC; PHARMACEUTICAL PREPARATIONS; VITREOUS BODY;

EID: 84916925894     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000399     Document Type: Review

References (104)

1. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-S19.
2. Williams GA. IVT injections: health policy implications. Rev Ophthalmol 2014;21:62-64.
3. RBRVS DataManager Online. Chicago, IL: American Medical Association.
4. Eylea (Package insert). Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2014.
5. Jetrea (Package insert). Iselin, NJ: ThromboGenics, Inc; 2012.
6. Lucentis (Package insert). South San Francisco, CA: Genentech, Inc; 2014.
7. Macugen (Package insert). Palm Beach Gardens, FL: Eyetech, Inc; 2011.
8. Ozurdex (Package insert). Irvine, CA: Allergan, Inc; 2014.
9. Triescence (Package insert). Fort Worth, TX: Alcon Laboratories, Inc; 2008.
10. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-1398.
11. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-2049.
12. Lang GE, Berta A, Eldem BM, et al; RESTORE Extension Study Group. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013;120:2004-2012.
13. Korobelnik JF, Holz FG, Roider J, et al; GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO Study. Ophthalmology 2014;121:202-208.
14. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004; 24:676-698.
15. Bhavsar AR, Googe JM Jr, Stockdale CR, et al; Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009;127:1581-1583.
16. Bhavsar AR, Stockdale CR, Ferris FL III, et al; Diabetic Retinopathy Clinical Research Network. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol 2012;130:809-810.
17. Storey P, Dollin M, Pitcher J, et al; Post-Injection Endophthalmitis Study Team. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology 2014;121:283-289.
18. Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609-1614.
19. Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina 2011;31:2032-2036.
20. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol 2011;129:1180-1188.
21. Dave SB, Toma HS, Kim SJ. Ophthalmic antibiotic use and multidrug-resistant staphylococcus epidermidis: a controlled, longitudinal study. Ophthalmology 2011;118:2035-2040.
22. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
23. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011;31:662-668.
24. Brown DM, Nguyen QD, Marcus DM, et al; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-2022.
25. Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 2011;152:266-272.
26. Shah CP, Garg SJ, Vander JF, et al; Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 2011;118: 2028-2034.
27. Fineman MS, Hsu J, Spirn MJ, Kaiser RS. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina 2013;33:1968-1970.
28. Park Y, Kim KS, Park YH. Acute endophthalmitis after intravitreal injection and preventive effect of preoperative topical antibiotics. J Ocul Pharmacol Ther 2013;29:900-905.
29. Shimada H, Hattori T, Mori R, et al. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol 2013;251:1885-1890.
30. Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology 2009;116:1498-1501.
31. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144:454-456.
32. Moss JM, Nguyen D, Liu YI, et al. Comparison of one-day versus one-hour application of topical gatifloxacin in eliminating conjunctival bacterial flora. Ophthalmology 2008;115: 2013-2016.
33. Ta CN, Egbert PR, Singh K, et al. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology 2002;109: 2036-2040; discussion 2040-2041.
34. Kim YJ, Sung KR, Lee KS, et al. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Am J Ophthalmol 2014;157:1266-1271.
35. Wehrli SJ, Tawse K, Levin MH, et al. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 2012;32:1295-1301.
36. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-1114.
37. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina 2013;33:179-187.
38. Kim D, Nam WH, Kim HK, Yi K. Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure? J Glaucoma 2014;23: 446-448.
39. Bakri SJ, Moshfeghi DM, Francom S, et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal agerelated macular degeneration clinical trials. Ophthalmology 2014;121:1102-1108.
40. American Academy of Ophthalmology Glaucoma Panel. Primary Open-Angle Glaucoma Suspect. San Francisco, CA: American Academy of Ophthalmology; 2010. Available at: http://www. guideline.gov/content.aspx?id=24811. Accessed June 19, 2014.
41. Trivedi D, Denniston AK, Murray PI. Safety profile of anterior chamber paracentesis performed at the slit lamp. Clin Exp Ophthalmol 2011;39:725-728.
42. Helbig H, Noske W, Kleineidam M, et al. Bacterial endophthalmitis after anterior chamber paracentesis. Br J Ophthalmol 1995;79:866.
43. Joondeph BC, Joondeph HC. Purulent anterior segment endophthalmitis following paracentesis. Ophthalmic Surg 1986; 17:91-93.
44. Olson JM, Scott IU, Kerchner DL, Kunselman AR. Association between systemic anticoagulation and rate of intraocular hemorrhage following intravitreal anti-VEGF therapy for agerelated macular degeneration. Ophthalmic Surg Lasers Imaging Retina 2013;44:455-459.
45. Moon SW, Oh J, Yu HG, et al. Incidence and risk factors for macular hemorrhage following intravitreal ranibizumab injection for neovascular age-related macular degeneration. J Ocul Pharmacol Ther 2013;29:556-559.
46. Dayani PN, Siddiqi OK, Holekamp NM. Safety of intravitreal injections in patients receiving warfarin anticoagulation. Am J Ophthalmol 2007;144:451-453.
47. Wykoff CC, Flynn HW Jr, Han DP. Allergy to povidoneiodine and cephalosporins: the clinical dilemma in ophthalmic use. Am J Ophthalmol 2011;151:4-6.
48. Dykes PJ, Marks R. An evaluation of the irritancy potential of povidone iodine solutions: comparison of subjective and objective assessment techniques. Clin Exp Dermatol 1992; 17:246-249.
49. Lachapelle JM. Allergic contact dermatitis from povidone iodine: a re-evaluation study. Contact Dermatitis 2005;52: 9-10.
50. Adachi A, Fukunaga A, Hayashi K, et al. Anaphylaxis to polyvinylpyrrolidone after vaginal application of povidone iodine. Contact Dermatitis 2003;48:133-136.
51. Gray PE, Katelaris CH, Lipson D. Recurrent anaphylaxis caused by topical povidone-iodine (Betadine). J Paediatr Child Health 2013;9:506-507.
52. Friedman DA, Mason JO III, Emond T, McGwin G Jr. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina 2013;33:975-981.
53. Safar A, Dellimore MC. The effect of povidone iodine flush versus drops on conjunctival colonization before intravitreal injections. Int Ophthalmol 2007;27:307-312.
54. Lyall DA, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond) 2012;26:1517-1526.
55. Scott IU, Flynn HW Jr, Feuer W. Endophthalmitis after secondary intraocular lens implantation. A case-report study. Ophthalmology 1995;102:1925-1931.
56. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654-661.
57. Casparis H, Wolfensberger TJ, Becker M, et al. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. Retina 2014;34:12-17.
58. Brynskov T, Kemp H, Sørensen TL. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina 2014;34:951-957.
59. Abell RG, Kerr NM, Allen P, Vote BJ. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol 2012; 96:1474-1478.
60. Tabandeh H, Boscia F, Sborgia A, et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina 2014;34:18-23.
61. Chao DL, Gregori NZ, Khandji J, Goldhardt R. Safety of bilateral intravitreal injections delivered in a teaching institution. Expert Opin Drug Deliv 2014;11:991-993.
62. Bakri SJ, Risco M, Edwards AO, Pulido JS. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol 2009;148:66-69.
63. Davis RP, Schefler AC, Murray TG. Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration. Clin Ophthalmol 2010; 4:703-707.
64. Lima LH, Zweifel SA, Engelbert M, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina 2009;29: 1213-1217.
65. Goldberg RA, Flynn HW Jr, Miller D, et al. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results. Ophthalmology 2013;120:1448-1453.
66. Small KW, Chan CK, Silva-Garcia R, Walsh TJ. Onset of an outbreak of Bipolaris hawaiiensis fungal endophthalmitis after intravitreal injections of triamcinolone. Ophthalmology 2014;121:952-958.
67. Sheyman AT, Cohen BZ, Friedman AH, Ackert JM. An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. JAMA Ophthalmol 2013;131:864-869.
68. Shienbaum G, Flynn HW Jr. Compounding bevacizumab for intravitreal injection: does USP ,797. always apply? Retina 2013;33:1733-1734.
69. Fungal meningitis outbreak. Available at: http://www.fda. gov/Safety/MedWatch/SafetyInformation/SafetyAlertsfor HumanMedicalProducts/ucm323946.htm. Accessed June 10, 2014.
70. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-882.
71. Webster J, Alghamdi A. Use of plastic adhesive drapes during surgery for preventing surgical site infection. Cochrane Database Syst Rev 2013;1:CD006353.
72. Fagan XJ, Al-Qureshi S. Intravitreal injections: a review of the evidence for best practice. Clin Experiment Ophthalmol 2013;41:500-507.
73. Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol 2011;151:329-332.
74. Tailor R, Beasley R, Yang Y, Narendran N. Evaluation of patients' experiences at different stages of the intravitreal injection procedure-what can be improved? Clin Ophthalmol 2011;5:1499-1502.
75. Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina 2012;32:473-476.
76. Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol 2011;129:1551-1554.
77. Friedman DA, Lindquist TP, Mason JO III, McGwin G. Needle contamination in the setting of intravitreal injections. Retina 2014;34:929-934.
78. Hsu J, Gerstenblith AT, Garg SJ, Vander JF. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics. Am J Ophthalmol 2014;157:514-518.
79. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 1991;98:1769-1775.
80. Trinavarat A, Atchaneeyasakul LO, Nopmaneejumruslers C, Inson K. Reduction of endophthalmitis rate after cataract surgery with preoperative 5% povidone-iodine. Dermatology 2006;212:35-40.
81. Wu PC, Li M, Chang SJ, et al. Risk of endophthalmitis after cataract surgery using different protocols for povidone-iodine preoperative disinfection. J Ocul Pharmacol Ther 2006;22:54-61.
82. Kim SJ, Chomsky AS, Sternberg P Jr. Reducing the risk of endophthalmitis after intravitreous injection. JAMA Ophthalmol 2013;131:674-675.
83. Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002;133:484-498.
84. Gregori NZ, Weiss MJ, Goldhardt R, et al. Ocular decompression with cotton swabs lowers intraocular pressure elevation after intravitreal injection. J Glaucoma 2014;23:508-512.
85. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
86. Blaha GR, Tilton EP, Barouch FC, Marx JL. Randomized trial of anesthetic methods for intravitreal injections. Retina 2011;31:535-539.
87. Davis MJ, Pollack JS, Shott S. Comparison of topical anesthetics for intravitreal injections: a randomized clinical trial. Retina 2012;32:701-705.
88. Kaderli B, Avci R. Comparison of topical and subconjunctival anesthesia in intravitreal injection administrations. Eur J Ophthalmol 2006;16:718-721.
89. Friedman SM, Margo CE. Topical gel vs subconjunctival lidocaine for intravitreous injection: a randomized clinical trial. Am J Ophthalmol 2006;142:887-888.
90. Page MA, Fraunfelder FW. Safety, efficacy, and patient acceptability of lidocaine hydrochloride ophthalmic gel as a topical ocular anesthetic for use in ophthalmic procedures. Clin Ophthalmol 2009;3:601-609.
91. Doshi RR, Leng T, Fung AE. Povidone-iodine before lidocaine gel anesthesia achieves surface antisepsis. Ophthalmic Surg Lasers Imaging 2011;42:346-349.
92. Boden JH, Myers ML, Lee T, et al. Effect of lidocaine gel on povidone-iodine antisepsis and microbial survival. J Cataract Refract Surg 2008;34:1773-1775.
93. Tustin A, Kim SJ, Chomsky A, et al. Antibacterial properties of 2% lidocaine and reduced rate of endophthalmitis after intravitreal injection. Retina 2014;34:935-942.
94. Méndez PC, Vázquez CM, Villar JO, Pazos JA. Assessment of the use of the speculum for intravitreal injections of anti-VEGF. Acta Ophthalmol 2013;91:e244-e246.
95. Rodrigues EB, Meyer CH, Grumann A Jr, et al. Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am J Ophthalmol 2007;143:1035-1037.
96. Knecht PB,Michels S, Sturm V, et al. Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. Retina 2009;29:1175-1181.
97. Özkaya A, Alkin Z, Celik U, et al. Comparing the effects of three different intravitreal injection techniques on vitreous reflux and intraocular pressure. J Ocul Pharmacol Ther 2013;29:325-329.
98. Höhn F, Mirshahi A. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application. Graefes Arch Clin Exp Ophthalmol 2010;248:1371-1375.
99. Karth PA, Blumenkranz MS. Update on intravitreal injection technique. Rev Ophthalmol 2014;21:76-81.
100. Rifkin L, Schaal S. Factors affecting patients' pain intensity during in office intravitreal injection procedure. Retina 2012; 32:696-700.
101. Hubschman JP, Coffee RE, Bourges JL, et al. Experimental model of intravitreal injection techniques. Retina 2010;30: 167-173.
102. Pulido JS, Pulido CM, Bakri SJ, et al. The use of 31-gauge needles and syringes for intraocular injections. Eye (Lond) 2007;21:829-830.
103. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006;113:1174-1178.
104. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930-934.